Literature DB >> 17043180

Successful treatment of mucous membrane pemphigoid with infliximab.

Michael P Heffernan1, Danette D Bentley.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 17043180     DOI: 10.1001/archderm.142.10.1268

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  7 in total

Review 1.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

2.  Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom.

Authors:  G P Williams; C Radford; P Nightingale; J K G Dart; S Rauz
Journal:  Eye (Lond)       Date:  2011-07-29       Impact factor: 3.775

3.  Bullous pemphigoid during ustekinumab therapy.

Authors:  Aurore Le Guern; Salim Alkeraye; Annie Vermersch-Langlin; Patrick Coupe; Marlène Vonarx
Journal:  JAAD Case Rep       Date:  2015-10-02

Review 4.  The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.

Authors:  Soheil Tavakolpour
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

Review 5.  Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.

Authors:  Yu-Kai Kuo; I-Chan Lin; Li-Nien Chien; Tzu-Yu Lin; Ying-Ting How; Ko-Hua Chen; Gregory J Dusting; Ching-Li Tseng
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

Review 6.  Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.

Authors:  Panagiotis Georgoudis; Francesco Sabatino; Nora Szentmary; Sotiria Palioura; Eszter Fodor; Samer Hamada; Hendrik P N Scholl; Zisis Gatzioufas
Journal:  Ophthalmol Ther       Date:  2019-01-29

7.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.